ClinicalTrials.gg
RecruitingNCT07179406Updated Jun 26, 2026

The Effect of Spinal Cord Stimulators on Restless Leg Syndrome

An interventional study of H-Reflex and Somatosensory evoked potential (SSEP) in Restless Leg Syndrome (RLS) and Spinal Cord Stimulation (SCS), sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Restless Legs Syndrome with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Restless Legs Syndrome · United States.

Planned enrollment
45th of 95
50 · median 46
Started
2025
with 3 others
No phase
30 of 107
5 open now
Primary completion
2028-01
later than 10 of 12 live
Registered
104th of 107
by date

Among the 107 studies in Restless Legs Syndrome with a site in United States, this one is the 45th largest by planned enrollment of the 95 interventional ones that give a count, is one of 4 that started in 2025, is one of 30 with no phase, reaches primary completion later than 10 of the 12 other live ones, and was the 104th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

9 of the 107 studies in Restless Legs Syndrome with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Restless Legs Syndrome with a site in United States, or all of them as a file.
02

Study summary

This study aims to evaluate neurophysiological responses and symptom changes in individuals with Restless Legs Syndrome (RLS) and/or chronic pain. Participants will undergo standard clinical assessments including EEG, EMG, h-reflex, SSEP, ERP, and TMS under varying SCS conditions.The study involves 4 arms. Arm 1 are individuals diagnosed with RLS and Healthy Controls. Arm 2 are individuals diagnosed with RLS and have an existing SCS. Arm 3 are individuals diagnosed with RLS and scheduled to receive a SCS. Arm 4 are individuals with chronic pain and have a SCS, but no diagnosis of RLS.

03

Conditions studied

  • Restless Leg Syndrome (RLS)
  • Spinal Cord Stimulation (SCS)

Keywords

  • SCS
  • Spinal Cord Stimulation
  • RLS
  • Restless Leg Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has Restless Leg Syndrome
  • No major changes in RLS medications in past 4 weeks
  • Willing and able to comply with study protocol
  • Healthy Controls - No RLS diagnosis
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Any mental or physical limitation that would prevent completing any of the studies
  • Currently using another device to treat RLS
  • Unable or unwilling to comply with study protocols
  • Other medical condition that would put the subject at risk as determined by the investigator
  • Pregnant, breastfeeding, or trying to become pregnant
  • Currently participating or planning to participate in any other clinical evaluation during the study period that may, in the opinion of the investigator, affect RLS
  • One or more of the following diseases: spinal cord injury, severe peripheral neuropathy or radiculopathy, severe psychiatric or cognitive disorder that may interfere with participation of the study, history of drug or alcohol abuse within the past year, epilepsy or seizure disorder, current active or chronic infection other than the common cold, within the past 5 years (not including basal cell or squamous cell skin cancer), severe movement disorder (i.e. Parkinson's disease), deep vein thrombosis, or multiple sclerosis.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Arm 1: Assessments and questionnaires only

    Complete questionnaires on RLS and pain Stimulation: H-reflex - A small electrical stimulus is provided to the leg and foot area and a measurement of the stimulus is taken by the EEG electrodes. Somatosensory evoked potential (SSEP) - A small electrical stimulus is provided to a nerve on the body and measured at several places along the nervous system (spinal cord, brain, etc.) with the EMG and EEG electrodes. Vibratory Electrophysiological Response Potential (ERP) - stimulation of the ankle with vibration sensations using a device like a buzzer and recording of body's responses using the EEG and/or EMG electrodes. Transcranial Magnetic Stimulation (TMS) - A small magnetic pulse is used to provide a small amount of electrical stimulation to nervous system. The EEG and/or EMG electrodes will be used to measure body's reaction.

    Other: H-Reflex · Other: Somatosensory evoked potential (SSEP) · Other: Vibratory Electrophysiological Response Potential (ERP) · Other: Transcranial Magnetic Stimulation (TMS)

  • Active comparator
    Arm 2: Off-on-off

    Participants will turn OFF their SCS at least 48 hours prior to the visit. The assessments listed in Arm 1 will be performed and the SCS will be turned ON for at least 60 minutes before repeating the assessments. Participants may repeat the questionnaires during this waiting period. Finally, the SCS is turned OFF again, this time for at least 30 minutes before repeating the assessments, except for the h-reflex, which will not be needed again. As with before, participants can complete the questionnaires during this waiting period.

    Other: H-Reflex · Other: Somatosensory evoked potential (SSEP) · Other: Vibratory Electrophysiological Response Potential (ERP) · Other: Transcranial Magnetic Stimulation (TMS) · Other: Spinal Cord Stimulator (SCS) manipulation

  • Active comparator
    Arm 3: Off-on-off post-op

    Participants will perform the same procedures as those in Arm 2, but only after 2-3 weeks from receiving a permanent SCS.

    Other: H-Reflex · Other: Somatosensory evoked potential (SSEP) · Other: Vibratory Electrophysiological Response Potential (ERP) · Other: Transcranial Magnetic Stimulation (TMS) · Other: Spinal Cord Stimulator (SCS) manipulation

  • Active comparator
    Arm 4: On-off-on

    Participants will have their SCS on for at least 48 hours prior to the visit. The assessments listed in Arm 1 will be performed and the SCS will be turned Off for at least 60 minutes before repeating the assessments. Participants may repeat the questionnaires during this waiting period. Finally, the SCS is turned On again, this time for at least 30 minutes before repeating the assessments, except for the h-reflex, which will not be needed again. As with before, participants can complete the questionnaires during this waiting period.

    Other: H-Reflex · Other: Somatosensory evoked potential (SSEP) · Other: Vibratory Electrophysiological Response Potential (ERP) · Other: Transcranial Magnetic Stimulation (TMS) · Other: Spinal Cord Stimulator (SCS) manipulation

Interventions

  • OtherH-Reflex

    H-reflex - A small electrical stimulus is provided to the leg and foot area and a measurement of the stimulus is taken by the EEG electrodes.

  • OtherSomatosensory evoked potential (SSEP)

    A small electrical stimulus is provided to a nerve on the body and measured at several places along the nervous system (spinal cord, brain, etc.) with the EMG and EEG electrodes.

  • OtherVibratory Electrophysiological Response Potential (ERP)

    stimulation is provided to the ankle with vibration sensations using a device like a buzzer and the recording of the body's responses using the EEG and/or EMG electrodes.

  • OtherTranscranial Magnetic Stimulation (TMS)

    A small magnetic pulse is used to provide a small amount of electrical stimulation to the nervous system. The EEG and/or EMG electrodes will be used to measure the body's reaction.

  • OtherSpinal Cord Stimulator (SCS) manipulation

    Spinal cord stimulator will be turned on/off

06

What researchers measure

Primary outcomes

  1. Changes in H-reflex neurophysiological activity in response to Spinal Cord Stimulation (SCS)

    Time frame: Up to 3 Weeks after consent to the study

  2. Changes in Somatosensory Evoked Potential (SSEP) activity in response to Spinal Cord Stimulation (SCS)

    Time frame: Up to 3 Weeks after consent to the study

  3. Changes in Vibratory Electrophysiological Response Potential (ERP) activity in response to Spinal Cord Stimulation (SCS)

    Time frame: Up to 3 Weeks after consent to the study

  4. Changes in Transcranial Magnetic Stimulation (TMS) activity in response to Spinal Cord Stimulation (SCS)

    Time frame: Up to 3 Weeks after consent to the study

Secondary outcomes

  1. Changes in self-reported RLS symptoms via International Restless Legs Syndrome (IRLSS) Questionnaire

    Time frame: Up to 3 Weeks after consent to the study

  2. Changes in self-reported pain symptoms via Promis Questionnaire

    Time frame: Up to 3 Weeks after consent to the study

  3. Changes in self-reported pain symptoms via PainDetect Questionnaire

    Time frame: Up to 3 Weeks after consent to the study

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jan 2028, 29 months after the start.

Of 46 non-industry interventional studies with no phase under Restless Legs Syndrome, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 42. This study's planned 29 months is above that.

Counting every sponsor, half of 53 studies reached it within 12 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2025
First posted
Sep 17, 2025
StartActual
Aug 4, 2025
Primary completionEst.
Jan 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07179406
Responsible party
Marshall Holland (Assistant Professor, University of Alabama at Birmingham) — Principal investigator
First posted
Sep 17, 2025
Start date
Aug 4, 2025
Primary completion
Jan 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jun 26, 2026

Study contacts

Marshall Holland, MD
Contact
mtholland@uabmc.edu
2059343411

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion